Akero Book Value Per Share from 2010 to 2024

AKRO Stock  USD 20.79  1.57  8.17%   
Akero Therapeutics Book Value Per Share yearly trend continues to be very stable with very little volatility. Book Value Per Share is likely to grow to 10.69 this year. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Akero Therapeutics according to its financial statements. View All Fundamentals
 
Book Value Per Share  
First Reported
2010-12-31
Previous Quarter
10.1830844
Current Value
10.69
Quarterly Volatility
5.62684668
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Akero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akero Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 3.3 M or Selling General Administrative of 16.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.49. Akero financial statements analysis is a perfect complement when working with Akero Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Akero Therapeutics Correlation against competitors.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

Latest Akero Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Akero Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Akero Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 12.24 X10 Years Trend
Slightly volatile
   Book Value Per Share   
       Timeline  

Akero Book Value Per Share Regression Statistics

Arithmetic Mean1.98
Coefficient Of Variation284.17
Mean Deviation5.20
Median(2.35)
Standard Deviation5.63
Sample Variance31.66
Range13.042
R-Value0.86
Mean Square Error8.96
R-Squared0.74
Significance0.000042
Slope1.08
Total Sum of Squares443.26

Akero Book Value Per Share History

2024 10.69
2023 10.18
2022 8.38
2021 4.86
2020 8.22
2019 8.54

Other Fundumenentals of Akero Therapeutics

Akero Therapeutics Book Value Per Share component correlations

About Akero Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Akero Therapeutics income statement, its balance sheet, and the statement of cash flows. Akero Therapeutics investors use historical funamental indicators, such as Akero Therapeutics's Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Akero Therapeutics investors may use each financial statement separately, they are all related. The changes in Akero Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Akero Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Akero Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Akero Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Book Value Per Share 10.18  10.69 
Tangible Book Value Per Share 10.18  10.69 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in Akero Stock

When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:
Check out the analysis of Akero Therapeutics Correlation against competitors.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.24)
Return On Assets
(0.20)
Return On Equity
(0.31)
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.